Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
NCT05413551Phase 1Completed
- Sponsor
- Stanford University
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of isoniazid in latent tuberculosis infection (LTBI) (3 arms), sponsored by Stanford University. Primary endpoints: Isoniazid Plasma Area-under-the-curve at Day 14 and Isoniazid Clearance at Day 14. Started Mar 2023; status: completed.
02
Drugs
isoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT05413551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413551.